Scalper1 News
Gilead Sciences beat third-quarter sales estimates and issued cautious guidance late Tuesday, as its bottom line was hit by an ObamaCare-related fee. The stock slipped 4% after hours following a new record high during the regular session. Gilead (GILD) revenue rose 117% to $6.04 billion, beating analysts’ consensus by about $50 million. Earnings leapt 254% to $1.84 a share, but 8 cents short of the Street’s estimate. But Gilead said Scalper1 News
Scalper1 News